A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
• Male or female adult ≥ 18 years of age;
• Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by
‣ BSA 10%
⁃ PGA ≥3
⁃ PASI ≥12
• Must be a candidate for phototherapy and/or systemic therapy
• Females of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.